MLN8237 in Head and Neck Cancer

NCT01540682 | Completed Phase 1 DMC

• 1 other identifier: UPCC 10311
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

This study will evaluate the initial safety and effectiveness of an investigational drug, MLN8237, added to routine radiation therapy and cetuximab in patients with head and neck cancer. This study will also determine the highest dose of MLN8237 that can be given together with cetuximab and radiation therapy without causing severe side effects.

Conditions

Head and Neck Cancer

Keywords

Male and female patients with HNSCC of the oral cavity, oropharynx, hypopharynx, larynx,; nasopharynx or paranasal sinuses that is considered appropriate; for definitive cetuximab-based radiation therapy.

Outcome Measures

Primary Outcomes (1)

• Number of Adverse Events

Interventions

MLN8237 DRUG

Three dose levels of MLN8237 are planned:30, 40 and 50 mg po bid.

Cetuximab DRUG

\~ 1 week prior to the initiation of radiation therapy and continuing for a grand total of 12 weeks.

Radiotherapy RADIATION

Radiotherapy will be administered in 2-Gy fractions, 5 days a week to a total dose of \~70 Gy.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or females greater than 18 years of age.
• ECOG performance status of 0-1
• Patients must have histologically or cytologically confirmed HNSCC of the oral cavity, oropharynx, hypopharynx, larynx, nasopharynx or paranasal sinuses that is considered after a multidisciplinary evaluation (surgery, medical oncology \& radiation oncology) to be appropriate for definitive cetuximab-based radiation therapy
• No distant metastatic disease. Minimum work-up includes:
• History/physical examination within 4 weeks prior to registration, including assessment of weight and weight loss in past 6 months and an examination by a Medical Oncologist
• PET/CT scan within 6 weeks prior to registration
• CT scan or MRI of the head and neck (of the primary tumor and neck nodes) within 4 weeks prior to registration
• Adequate organ and marrow function
• Negative pregnancy test within 2 weeks prior to registration for women of childbearing potential. The effects of MLN8237 on the developing human fetus are unknown. For this reason and because MLN8237 agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
• Male subject agrees to use an acceptable method for contraception during the entire study treatment period through 4 months after the last dose of MLN8237.
• Ability to understand and willingness to sign a written informed consent document with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

You may not qualify if:

• Systemic anti-neoplastic treatment within 21 days preceding the first dose of MLN8237. Patients treated with non-cytotoxic small molecule drugs (eg, tyrosine kinase inhibitors, such as erlotinib and hormonal agents, such as letrozole) must not have received treatment with these drugs for at least 2 weeks before the first dose of MLN8237 is administered.
• Patient has already had definitive surgical treatment, excluding diagnostic biopsy of the primary site or nodal sampling of neck disease. Prior radical or modified neck dissection is also not permitted.
• Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
• Primary tumor site is skin or salivary gland.
• Uncorrected CTCAE, v. 4.0 grade 3-4 electrolyte abnormalities
• Patients may not be receiving any other investigational agents or treatment with any investigational products within 21 days before the first dose of study drug.
• Patients with known brain metastasis are excluded from this clinical trial because of their poor prognosis and because they often develop rapid progressive neurologic dysfunction that would confound the evaluation of neurological and other adverse events.
• History of known allergic reactions attributed to compounds of similar chemical or biologic composition to MLN8237 or cetuximab.
• Patients may not be taking proton pump inhibitors, H2 antagonists or pancreatic enzyme replacement. Subjects who refuse to limit use of alcohol are also excluded.
• Severe, active co-morbidity
• Clinical evidence of intestinal malabsorption. Examples include resection of pancreas or upper small bowel, requirement for pancreatic enzymes, or any other condition that would modify small bowel absorption of oral medications.
• Prior treatment with high-dose chemotherapy, defined as chemotherapy requiring the use of peripheral blood or bone marrow stem cell support for hematopoietic reconstitution, including prior allogeneic bone marrow transplantation.
• Prior radiotherapy to greater or equal to 25% of bone marrow. Whole pelvic radiation is considered to be over 25%.
• Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
• Major surgery within 14 days prior to the first dose of study drug treatment.

Sponsors & Collaborators

• Abramson Cancer Center at Penn Medicine: lead

Study Sites (1)

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

MeSH Terms

Conditions

Head and Neck Neoplasms; Laryngeal Diseases

Interventions

MLN 8237; Cetuximab; Radiotherapy

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Respiratory Tract Diseases; Otorhinolaryngologic Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Therapeutics

Study Officials

• Roger Cohen, MD

  Abramson Cancer Center at Penn Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 9, 2012
• First Posted: February 29, 2012
• Study Start: February 1, 2012
• Primary Completion: November 1, 2015
• Last Updated: August 29, 2018

Record last verified: 2018-08

Locations

US (1)